REPLIMUNE GROUP, INC. (REPL) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -296.97M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-296.97M | (m) |
| 2026-03-31 | (m) | $-313.94M | (m) |
| 2025-12-31 | (m) | $-314.85M | (m) |
| 2025-09-30 | (m) | $-310.26M | (m) |
| 2025-06-30 | (m) | $-280.22M | (m) |
| 2025-03-31 | (m) | $-247.30M | (m) |
| 2024-12-31 | (m) | $-228.24M | (m) |
| 2024-09-30 | (m) | $-213.02M | (m) |
| 2024-06-30 | (m) | $-220.01M | (m) |
| 2024-03-31 | (m) | $-215.79M | (m) |
| 2023-12-31 | (m) | $-209.96M | (m) |
| 2023-09-30 | (m) | $-198.53M | (m) |
| 2023-06-30 | (m) | $-181.59M | (m) |
| 2023-03-31 | (m) | $-174.28M | (m) |
| 2022-12-31 | (m) | $-156.74M | (m) |
| 2022-09-30 | (m) | $-146.72M | (m) |
| 2022-06-30 | (m) | $-132.98M | (m) |
| 2022-03-31 | (m) | $-118.04M | (m) |
| 2021-12-31 | (m) | $-107.84M | (m) |
| 2021-09-30 | (m) | $-99.95M | (m) |
| 2021-06-30 | (m) | $-90.69M | (m) |
| 2021-03-31 | (m) | $-80.87M | (m) |
| 2020-12-31 | (m) | $-75.16M | (m) |
| 2020-09-30 | (m) | $-69.57M | (m) |
| 2020-06-30 | (m) | $-60.61M | (m) |
| 2020-03-31 | (m) | $-52.63M | (m) |
| 2019-12-31 | (m) | $-43.49M | (m) |
| 2019-09-30 | (m) | $-34.98M | (m) |
| 2019-06-30 | (m) | $-30.30M | (m) |
| 2019-03-31 | (m) | $-30.83M | (m) |
| 2018-12-31 | (m) | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | $-19.70M | (m) |
| 2017-12-31 | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | $-7.70M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |